| HOME >> BIOLOGY >> TECHNOLOGY |
490,595(d)
2,055,817(c)
1,990,980(e)Income from operations38,951(a)
28,860(d)
180,629(c)
47,493(e)Other expense, net: Interest expense, net3394301,97952 Foreign exchange transaction loss, net3561,0541,2483,649 Impairment of equity investment12,119-12,119-Other expense, net12,814(b)
1,48415,346(b)
3,701Income before taxes and equity investee earnings26,137(a),(b)
27,376(d)
165,283(b),(c)
43,792(e)Tax expense (benefit)5,172(a),(b)
(1,121)(d)
33,574(b),(c)
(23,655)(e)Equity investee earnings (loss)175(119)480807Net income$
21,140(a),(b)
$
28,378(d)
$
32,189(b),(c)
$
8,254(e)Basic earnings per share$
.35(a),(b)
$
.46(d)
$
2.22(b),(c)
$
.08(e)Weighted average shares outstanding - basic59,730,27061,390,96559,629,78863,043,561Diluted earnings per share$
.35(a),(b)
$
.45(d)
$
2.16(b),(c)
$
.06(e)Weighted average shares outstanding - diluted61,080,38762,703,69061,091,35464,472,326(a) Includes, as applicable, $8,667 in restructuring costs ($5,961 net of tax), $10,287 in costs associated with the termination of an inventory supply agreement and related inventory write-down ($7,130 net of tax) and favorable income tax items totaling $1,769 during the three months ended December, 2011.(b) Includes $12,119 impairment of equity investment ($12,119 net of tax) during the three and twelve months ended December 31, 2011.(c) Includes, as applicable, $24,369 in restructuring costs ($16,067 net of tax), $10,287 in costs associated with the termination of an inventory supply agreement and related inventory write-down ($7,130 net of tax) and favorable
'/>"/>
| SOURCE Covance Inc. Copyright©2010 PR Newswire. All rights reserved |